18
Participants
Start Date
July 31, 2011
Primary Completion Date
October 31, 2015
Study Completion Date
July 31, 2016
²¹²Pb-TCMC-Trastuzumab
The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
trastuzumab
4 mg/kg.
University Of Alabama at Birmingham, Birmingham
UCSD Moores Cancer Center, San Diego
Orano Med LLC
INDUSTRY